Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020763

« Back to Dashboard
NDA 020763 describes AMERGE, which is a drug marketed by Glaxosmithkline Llc and is included in one NDA. It is available from one supplier. Additional details are available on the AMERGE profile page.

The generic ingredient in AMERGE is naratriptan hydrochloride. There are six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the naratriptan hydrochloride profile page.

Summary for NDA: 020763

Glaxosmithkline Llc
naratriptan hydrochloride
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 020763

Suppliers and Packaging for NDA: 020763

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
naratriptan hydrochloride
TABLET;ORAL 020763 NDA GlaxoSmithKline LLC 0173-0561 0173-0561-00 9 TABLET, FILM COATED in 1 BLISTER PACK (0173-0561-00)
naratriptan hydrochloride
TABLET;ORAL 020763 NDA GlaxoSmithKline LLC 0173-0562 0173-0562-00 9 TABLET, FILM COATED in 1 BLISTER PACK (0173-0562-00)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2.5MG BASE
Approval Date:Feb 10, 1998TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:Feb 10, 1998TE:ABRLD:No

Expired Orange Book Patents for NDA: 020763

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc
naratriptan hydrochloride
TABLET;ORAL020763-002Feb 10, 19984,997,841► subscribe
Glaxosmithkline Llc
naratriptan hydrochloride
TABLET;ORAL020763-001Feb 10, 19984,997,841► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.